Out Of The Pipeline
Out Of The Pipeline
Long-acting injectable aripiprazole for adult schizophrenia
Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia
Out Of The Pipeline
Inhaled loxapine for agitation
Reformulation allows for direct administration to the lungs, resulting in rapid absorption into systemic circulation
Out Of The Pipeline
Vilazodone for major depressive disorder
Vilazodone improved scores on multiple depression rating scales compared with placebo and was well tolerated
Out Of The Pipeline
Dextromethorphan/quinidine for pseudobulbar affect
The combination of dextromethorphan and quinidine reduced the number of daily PBA episodes in 3 randomized trials
Out Of The Pipeline
Lurasidone for schizophrenia
A new atypical antipsychotic offers once-daily dosing and is well tolerated and considered weight neutral
Out Of The Pipeline
Trazodone extended release for major depressive disorder
Once-daily dosing eliminates peaks and troughs in serum concentration seen with the immediate release formulation
Out Of The Pipeline
Doxepin for insomnia
Low-dose doxepin may relieve sleep maintenance insomnia and is not designated as a controlled substance
Out Of The Pipeline
Guanfacine extended release for ADHD
Once-daily formulation may improve adherence and control symptoms across a full day
Out Of The Pipeline
Asenapine for schizophrenia and bipolar I disorder
Receptor binding profile and sublingual delivery distinguish asenapine from other atypical antipsychotics
Out Of The Pipeline
Iloperidone for schizophrenia
New treatment option for patients who have not fully responded to or cannot tolerate other antipsychotics
Out Of The Pipeline
Transcranial magnetic stimulation for depression
FDA approves a new option for patients who fail 1 antidepressant trial